Published in Acta Crystallogr D Biol Crystallogr on October 22, 2009
A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol (2011) 1.84
Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A (2014) 1.44
Application of protein engineering to enhance crystallizability and improve crystal properties. Acta Crystallogr D Biol Crystallogr (2010) 1.38
The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2. J Infect Dis (2015) 0.80
A convenient and general expression platform for the production of secreted proteins from human cells. J Vis Exp (2012) 0.79
Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol (2016) 0.78
Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein. J Virol (2016) 0.75
Novel cross-reactive monoclonal antibodies against Ebolavirus glycoproteins show protection in a murine challenge model. J Virol (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Solvent content of protein crystals. J Mol Biol (1968) 106.07
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Automated MAD and MIR structure solution. Acta Crystallogr D Biol Crystallogr (1999) 41.65
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr (2001) 21.01
Maximum-likelihood density modification. Acta Crystallogr D Biol Crystallogr (2000) 20.67
Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc (2007) 19.50
The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr (1999) 19.10
Automated structure solution with autoSHARP. Methods Mol Biol (2007) 14.67
X-ray structure of a voltage-dependent K+ channel. Nature (2003) 14.50
The Jpred 3 secondary structure prediction server. Nucleic Acids Res (2008) 13.32
Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys J (1999) 13.18
Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science (1995) 12.94
Methods used in the structure determination of bovine mitochondrial F1 ATPase. Acta Crystallogr D Biol Crystallogr (1996) 11.90
Determination of domain structure of proteins from X-ray solution scattering. Biophys J (2001) 10.39
Automated main-chain model building by template matching and iterative fragment extension. Acta Crystallogr D Biol Crystallogr (2002) 10.34
MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res (2004) 9.86
NPS@: network protein sequence analysis. Trends Biochem Sci (2000) 9.68
Rapid automated molecular replacement by evolutionary search. Acta Crystallogr D Biol Crystallogr (1999) 8.97
Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure. EMBO J (1990) 8.46
Substructure search procedures for macromolecular structures. Acta Crystallogr D Biol Crystallogr (2003) 6.85
Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat (2003) 6.28
Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology (2004) 6.13
Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc (2007) 6.11
The DISOPRED server for the prediction of protein disorder. Bioinformatics (2004) 5.98
Crystal structure of Escherichia coli MscS, a voltage-modulated and mechanosensitive channel. Science (2002) 5.82
Advantages of combined transmembrane topology and signal peptide prediction--the Phobius web server. Nucleic Acids Res (2007) 5.29
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell (1998) 4.73
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr A (1990) 4.11
Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem (1989) 3.99
Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res (1993) 3.89
Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement. Proc Natl Acad Sci U S A (1997) 3.64
Structure at 2.7 A resolution of the Paracoccus denitrificans two-subunit cytochrome c oxidase complexed with an antibody FV fragment. Proc Natl Acad Sci U S A (1997) 3.57
Low-resolution structures of proteins in solution retrieved from X-ray scattering with a genetic algorithm. Biophys J (1998) 3.47
Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44
Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A (1999) 3.23
Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol (1998) 2.99
Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat Struct Biol (2003) 2.93
Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem (1999) 2.85
Advances in direct methods for protein crystallography. Curr Opin Struct Biol (1999) 2.85
pdb-care (PDB carbohydrate residue check): a program to support annotation of complex carbohydrate structures in PDB files. BMC Bioinformatics (2004) 2.70
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Comprehensive analysis of ebola virus GP1 in viral entry. J Virol (2005) 2.56
Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J (1999) 2.40
Glycoprotein structural genomics: solving the glycosylation problem. Structure (2007) 2.40
Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev (2002) 2.02
Considerations for the refinement of low-resolution crystal structures. Acta Crystallogr D Biol Crystallogr (2006) 2.02
GlyProt: in silico glycosylation of proteins. Nucleic Acids Res (2005) 1.97
Antibody elbow angles are influenced by their light chain class. J Mol Biol (2006) 1.96
Yeast RNA polymerase II at 5 A resolution. Cell (1999) 1.90
Reconstruction of protein form with X-ray solution scattering and a genetic algorithm. J Mol Biol (2000) 1.90
Biosynthesis and role of filoviral glycoproteins. J Gen Virol (2001) 1.84
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J Biol Chem (1990) 1.72
Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis (1999) 1.65
Molecular replacement by evolutionary search. Acta Crystallogr D Biol Crystallogr (2001) 1.29
Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J Virol Methods (2007) 1.27
Calcium phosphate transfection. Curr Protoc Mol Biol (2003) 1.22
The use of antibody fragments for crystallization and structure determinations. Structure (1995) 1.18
Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther (2003) 1.17
Preparation and crystallization of a human immunodeficiency virus p24-Fab complex. Proc Natl Acad Sci U S A (1990) 1.13
Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol (2007) 1.11
Deglycosylation of proteins for crystallization using recombinant fusion protein glycosidases. Protein Sci (1996) 1.04
An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Nat Protoc (2009) 1.01
Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells. J Biol Chem (1997) 0.97
Highly efficient selenomethionine labeling of recombinant proteins produced in mammalian cells. Protein Sci (2006) 0.96
Ping-pong cross-validation in real space: a method for increasing the phasing power of a partial model without risk of model bias. Acta Crystallogr D Biol Crystallogr (2003) 0.89
The suitability of multi-metal clusters for phasing in crystallography of large macromolecular assemblies. Structure (1996) 0.88
Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics (2005) 0.81
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Toward an AIDS vaccine. Science (2008) 4.83
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol (2003) 2.34
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A (2011) 2.12
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A (2008) 2.09
Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS (2007) 2.03
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol (2006) 1.90
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog (2013) 1.85
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol (2011) 1.84
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol (2003) 1.78
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A (2012) 1.74
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology (2007) 1.74
Accelerating next-generation vaccine development for global disease prevention. Science (2013) 1.73
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods (2010) 1.71
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med (2010) 1.71